MX2017016438A - Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit. - Google Patents

Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit.

Info

Publication number
MX2017016438A
MX2017016438A MX2017016438A MX2017016438A MX2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A MX 2017016438 A MX2017016438 A MX 2017016438A
Authority
MX
Mexico
Prior art keywords
methods
chimeric polypeptide
vaccine against
kit
immunization
Prior art date
Application number
MX2017016438A
Other languages
Spanish (es)
Inventor
Elizabeth Wilkowsky Silvina
Manuel Jaramillo Ortiz José
Paula Del Medico Zajac Maria
Calamante Gabriela
Original Assignee
Instituto Nac De Tecnologia Agropecuaria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Tecnologia Agropecuaria filed Critical Instituto Nac De Tecnologia Agropecuaria
Publication of MX2017016438A publication Critical patent/MX2017016438A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A61K39/018—Babesia antigens, e.g. Theileria antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

A chimeric polypeptide containing a fragment of MSA-2c antigen bound to a fragment of RAP-1 antigen bound to a fragment of HSP20 antigen, where the antigens are antigens of a Babesia genus parasite. For example, the chimeric polypeptide may be represented by an amino acid sequence which contains at least 89% identity in relation to SEQ ID N° 1. It shows a composition for a vaccine against babesiosis, immunization methods and detection methods.
MX2017016438A 2015-06-22 2016-06-22 Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit. MX2017016438A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP150101988A AR100931A1 (en) 2015-06-22 2015-06-22 CHEMICAL POLIPEPTIDE, VACCINE AGAINST BABESIOSIS, IMMUNIZATION METHODS, DETECTION METHODS AND KIT
PCT/US2016/038611 WO2016209859A1 (en) 2015-06-22 2016-06-22 Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit

Publications (1)

Publication Number Publication Date
MX2017016438A true MX2017016438A (en) 2018-08-15

Family

ID=57585545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016438A MX2017016438A (en) 2015-06-22 2016-06-22 Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit.

Country Status (5)

Country Link
AR (1) AR100931A1 (en)
BR (1) BR112017027804A2 (en)
CO (1) CO2018000255A2 (en)
MX (1) MX2017016438A (en)
WO (1) WO2016209859A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760137B2 (en) * 2017-07-18 2020-09-01 Roche Molecular Systems, Inc. Compositions and methods for detection of Babesia
CN113740529B (en) * 2021-08-25 2023-05-26 华中农业大学 Babesia canis antibody latex agglutination detection kit and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710009B2 (en) * 2004-05-26 2014-04-29 The Texas A&M University System HSP20 inhibits amyloidogenesis and neurotoxicity
RU2599544C2 (en) * 2010-12-29 2016-10-10 Интервет Интернэшнл Б.В. Canine babesiosis vaccine antigen

Also Published As

Publication number Publication date
CO2018000255A2 (en) 2018-04-19
AR100931A1 (en) 2016-11-09
BR112017027804A2 (en) 2018-08-28
WO2016209859A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
MX2017008187A (en) Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies.
MX2018011425A (en) Dna antibody constructs and method of using same.
MX2018001213A (en) Novel methods for inducing an immune response.
NZ729519A (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
AR110321A1 (en) ANTITAU ANTIBODIES AND METHODS OF USE
WO2015134722A3 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
MX348071B (en) Fc variants.
MX2017000836A (en) Listeria-based immunogenic compositions for eliciting anti-tumor responses.
CY1119916T1 (en) IMMUNE COMPOSITION
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2016002937A (en) Oncology vaccine.
MX2017005642A (en) Anti-ang2 antibodies and methods of use.
WO2015107363A3 (en) Mycobacterial antigen composition
BR112012031211A2 (en) methods and vaccine to reduce campylobacter infection
BR112017018703A2 (en) peptide derived from gpc3, pharmaceutical composition for treating or preventing cancer using the same, inducing immunity, and method for producing antigen presenting cells
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ725212A (en) Group a streptococcus vaccine
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
WO2018172259A3 (en) Improved li vaccine adjuvant
MX2017016438A (en) Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection methods and kit.
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
MX2019007924A (en) Influenza vaccines.